Patents by Inventor Eric ARMENTANI

Eric ARMENTANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified IL-2 polypeptides and uses thereof
    Patent number: 12521441
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: January 13, 2026
    Assignee: Bright Peak Therapeutics AG
    Inventors: Vijaya Raghavan Pattabiraman, Roberto Iacone, Jean-Philippe Carralot, Matilde Arévalo-Ruiz, Jeffrey William Bode, Alexander Mayweg, Fränzi Weibel, Anna Haydn, Régis Boehringer, Görkem Kurtuldu Sahin, Claudia Fetz, Camille Delon, Eric Armentani, Alexander Flohr, Giorgio Ottaviani
  • IL-7 POLYPEPTIDES, IMMUNOCYTOKINES COMPRISING SAME, AND USES THEREOF
    Publication number: 20240424127
    Abstract: The present disclosure relates to IL-7 polypeptides, compositions comprising IL-7 polypeptides, methods of making the same, and methods of using the IL-7 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the IL-7 polypeptides. In some embodiments, the disclosed IL-7 polypeptides comprise at least one modification at an amino acid residue which reduces the affinity of the IL-7 polypeptide to the IL-7 receptor. Also provided herein are synthetic IL-7 polypeptides and methods of manufacture thereof. Further provided herein are immunocytokines comprising immune checkpoint inhibitor molecules, such as anti-PD-1 antibodies, couple to the IL-7 polypeptides provided herein.
    Type: Application
    Filed: January 10, 2024
    Publication date: December 26, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Bertolt KREFT, Matilde ARÉVALO-RUIZ, Eric ARMENTANI
  • MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF
    Publication number: 20240207417
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Application
    Filed: January 27, 2023
    Publication date: June 27, 2024
    Inventors: Vijaya Raghavan PATTABIRAMAN, Roberto IACONE, Jean-Philippe CARRALOT, Matilde ARÉVALO-RUIZ, Jeffrey William BODE, Alexander MAYWEG, Fränzi WEIBEL, Anna HAYDN, Régis BOEHRINGER, Görkem KURTULDU SAHIN, Claudia FETZ, Camille DELON, Eric ARMENTANI, Alexander FLOHR, Giorgio OTTAVIANI
  • Modified IL-2 polypeptides and uses thereof
    Patent number: 11633488
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: April 25, 2023
    Assignee: Bright Peak Therapeutics AG
    Inventors: Vijaya Raghavan Pattabiraman, Roberto Iacone, Jean-Philippe Carralot, Matilde Arévalo-Ruiz, Jeffrey William Bode, Alexander Mayweg, Fränzi Weibel, Anna Haydn, Régis Boehringer, Görkem Kurtuldu Sahin, Claudia Fetz, Camille Delon, Eric Armentani, Alexander Flohr, Giorgio Ottaviani
  • MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF
    Publication number: 20210252157
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Vijaya Raghavan PATTABIRAMAN, Roberto IACONE, Jean-Philippe CARRALOT, Matilde ARÉVALO-RUIZ, Jeffrey William BODE, Alexander MAYWEG, Fränzi WEIBEL, Anna HAYDN, Régis BOEHRINGER, Görkem KURTULDU SAHIN, Claudia FETZ, Camille DELON, Eric ARMENTANI, Alexander FLOHR, Giorgio OTTAVIANI